Mammalian cell culture capabilities

Fujifilm Diosynth Biotechnologies offers wide range of biopharmaceutical contract manufacturing services which includes mammalian cell culture manufacturing facilities. It belongs to gmp contract manufacturing services category. It includes a purpose-built, state-of-the-art single-use facility opened in oc...

Fujifilm Diosynth Biotechnologies offers wide range of biopharmaceutical contract manufacturing services which includes microbial manufacturing facilities. It belongs to gmp contract manufacturing services category. It offers fully flexible facilities that are fda and mhra inspected. We can also offer deve...

As part of $850 million investment package, CDMO will double US cell culture production for recombinant vaccines and increase UK gene therapy production tenfold

FUJIFILM Diosynth Biotechnologies is a leading provider of cell culture services for biologics, advancing anddelivering life changing therapies. We offer complete solutions for cell line development, process development,late phase activities, clinical and commercial manufacturing of a wide variety of biopharmaceuticals.

While the COVID-19 pandemic has created even greater demand for partnerships, CDMOs need to be aware that the needle has shifted, creating both opportunities and challenges and changing how the services industry does business

Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021

CDMO subsidiary Fujifilm Diosynth Biotechnologies will operate the site which is expected to be operational in 2025

Investment will double the site's drug substance manufacturing capacity and will expand its capabilities to include fill/finish, and enhance its current assembly, labeling and packaging services.

Fujifilm Diosynth Biotechnologies will triple microbial production capacity at its UK Teesside facility after joint owner Fujifilm Corporation pledged to invest 9 billion yen (USD83 million) in the biologics focused CDMO.